enomimeran

Enomimeran (BNT111) is an intravenous therapeutic mRNA cancer vaccine developed by BioNTech. It is the lead candidate from BioNTech's FixVac platform, designed to stimulate a potent and specific immune response against melanoma cells. The vaccine consists of four mRNAs encoding a fixed combination of melanoma-associated antigens (MAAs): NY-ESO-1, tyrosinase, MAGE-A3, and TPTE. These mRNAs are formulated in a proprietary RNA-lipoplex (RNA-LPX) delivery system, which not only protects the mRNA but also acts as an intrinsic adjuvant by activating Toll-like receptors (TLR7/8). Enomimeran is primarily being investigated for the treatment of advanced or metastatic melanoma, both as a monotherapy and in combination with immune checkpoint inhibitors such as pembrolizumab, to overcome resistance and enhance anti-tumor T-cell activity.

Other names

BNT111 mRNA vaccineBNT-111 mRNA vaccineBNT 111 mRNA vaccine